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Objectives: To describe the prevalence and sensitivity of bacterias isolated in
respiratory secretions of controled children in the cystic ﬁbrosis Unit of our hospital
between the year of 1995–2009.
Methodology: We included 59 patients with cystic ﬁbrosis, from where we selected
one sputum culture per month and the sensitivity to positive cultures.
Results: 4264 sputum cultures were studied, of whom 1997 have been positive with
2606 bacterias. We discovered an increasing of samples as well as a decrease in the
quantity of positive cultures, with 66.7% of positive cultures in 1995 and 29.7%
in 2009. The most common bacterias were: Staphylococcus aureus (1078), Pseu-
domonas aeruginosa (512), Burkolderia cepacia complex (440) and Enterobacteri-
aceae (163). We have observed a decrease in Pseudomonas aeruginosa, Burkolderia
cepacia complex and an increased of Staphylococcus aureus and Stenotrophomonas.
The Burkolderia cepacia complex, Stenotrophomonas and Achromobacter have
shown high resistance to antibiotics, and Pseudomonas aeruginosa has a resistance
less than 5−10% against colimycin, tobramycin and ciproﬂoxacin.
Conclusions: Staphylococcus aureus and Pseudomonas aeruginosa continue being
the most common bacterias present in patients with cystic ﬁbrosis. We associated
the decrease in the prevalence of Pseudomonas aeruginosa with implementation
of newborn screening, better treatment guidelines and more effective control of
cross infection. The emergence of new pathogens such as Stenotrophomonas and
Achromobacter is smaller, but important, because together with the Burkholderia
cepacia shows resistance to usual antibiotics.
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Background: Current strategies of P. aeruginosa eradication are based on microbi-
ological surveillance by samples obtained from upper respiratory airways. However,
these do not realibly predict its bronchial presence in young CF children.
Hypothesis: Bronchoalveolar lavage (BAL) obtained by ﬂexible bronchoscopy
could give reliable information and avoid the inappropriate suppression of erad-
ication treatment.
Objectives:
1. To assess BAL in children in whom oropharyngeal or sputum cultures remain
negative from the beginning of inhaled treatment.
2. To study the relationship among infection and inﬂammation across the citology
of BAL.
3. To evaluate safety and side-effects of the test.
Methods: Prospective study of CF children (1997–2009) with repeatedly negative
cultures during the year after ﬁrst P. aeruginosa isolation. Performance of ﬂexible
bronchoscopy with BAL previously to the withdrawal of inhaled treatment.
Results: 36 bronchoscopies were carried out on 30 patients (64% female, 34%
male). Medium age of ﬁrst isolation was 33 months. BAL cultures were positive
in 11 cases (30.5%). There were no differences between sex, age of diagnosis or
ﬁrst isolation and kind of eradication treatment. Neutrophilic inﬂammation was
signiﬁcantly greater in positive BAL samples (p< 0.001). Adverse events reported
were clinically minor as cough (39%), temporary desaturations <90% (13.8%) and
fever (2.7%).
Conclusions: Bronchoscopy in CF children reveals a signiﬁcant prevalence of
previous undetected infection, therefore it should be carried out as previous control
of the ending of eradication treatment. It is a safe technique and the cytology of
BAL correlates infection and inﬂammation.
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Background: Chronic Pseudomonas aeruginosa (Pa) infection worsens the prog-
nosis of patients with Cystic Fibrosis (CF). Early Pa infection may be amenable to
eradication. We investigated the beneﬁts and harms of 4 anti-pseudomonal antibiotic
treatments in CF children at their ﬁrst Pa positive respiratory culture.
Methods: In a multicenter trial, CF children ages 1−12 years were randomized
to receive treatment on a scheduled quarterly basis (cycled therapy) or if Pa was
recovered from quarterly respiratory cultures (culture-based therapy), for a total of
6 quarters. At each cycle, participants received inhaled tobramycin (300mg BID)
for 28 days, with either oral ciproﬂoxacin (15−20mg/kg BID) or oral placebo
for 14 days. The primary endpoints were time to pulmonary exacerbation and
proportion of Pa-positive respiratory cultures.
Results: 304 subjects (76 participants in each of the 4 groups) qualiﬁed for
inclusion. There were no differences in exacerbations between cycled and culture-
based groups (HR 0.95, 95% CI 0.54, 1.66) or between ciproﬂoxacin and placebo
(HR, 1.45, 95% CI 0.82, 2.54). There were no differences in the relative odds of
Pa-positive cultures comparing cycled vs. culture-based group (OR 0.89, 95% CI
0.58, 1.37) or ciproﬂoxacin vs. placebo (OR 0.80; 95%CI 0.58, 1.09). Adverse
events were similar in all groups.
Conclusions: More intensive prophylactic (cycled) inhaled aminoglycoside treat-
ment did not reduce exacerbations or prevalence of Pa positive cultures compared
with an approach based on microbiological ﬁndings. There were no beneﬁts of
adding ciproﬂoxacin. There were no concerns with regard to drug toxicity or
emergence of resistant pathogens.
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It is known that inhaled antibiotic therapy (AB) delays pulmonary progression
and quality of life in cystic ﬁbrosis (CF) patients with Pseudomonas aeruginosa
infection (Pa). Since 2009 Bramitob, TOBI, Colistin are registered in Russia. Before
this period our patients received i.v. forms of gentamycin and tobramycin for
inhalation treatment.
Aim: Compare 3 Pa- inhaled antibiotic treatments in CF patients with ﬁrst isolate
and chronic Pa infection.
Method: Bramitob group − 21 patients (6−18 years) all with chronic infection,
TOBI group − 11 patients (3−15 years) 2 of them with ﬁrst isolate and 9 with
chronic infection, Colistin − 9 patients (0−15 years) 6 of them with ﬁrst isolate and
3 with chronic infection.
Result: In Bramitob group eradication of Pa was in 7/21 patients, in TOBI group in
1/2 of patient with ﬁrst isolate and in 6/9 with chronic infection, in Colistin group
in 4/6 of patients with ﬁrst isolate and in 2/3 children with chronic Pa infection. In
most of our patients we revealed improvement of lung function and nutritional status
and decrease in number of exacerbations of chronic bronchopulmanory process.
Conclusion: Equal clinical efﬁciency and safety of Bramitob, Colistin and TOBI
was shown. Russian CF patients have the opportunity to receive anti-pseudomonas
inhalation treatment according to the European standards now.
